TRUST-II: a global phase II study of taletrectinib in ROS1-positive non-small-cell lung cancer and other solid tumors.
Nagasaka M, Ohe Y, Zhou C, Choi CM, Yang N, Liu G, Felip E, Pérol M, Besse B, Nieva J, Raez L, Pennell NA, Dimou A, Marinis F, Ciardiello F, Seto T, Hu Z, Pan M, Wang W, Li S, Ou SI.
Nagasaka M, et al. Among authors: li s.
Future Oncol. 2023 Jan;19(2):123-135. doi: 10.2217/fon-2022-1059. Epub 2023 Mar 6.
Future Oncol. 2023.
PMID: 36877099